Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Lorenzo Falchi
No relevant relationships to disclose
Michael J. Keating
Consultant or Advisory Role - Celgene; GlaxoSmithKline
Honoraria - Celgene; GlaxoSmithKline
Xavier C. Badoux
No relevant relationships to disclose
William G. Wierda
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene; GlaxoSmithKline
Susan Mary O'Brien
Consultant or Advisory Role - Celgene; GlaxoSmithKline
Susan C. Smith
No relevant relationships to disclose
Sijin Wen
No relevant relationships to disclose
Hagop Kantarjian
No relevant relationships to disclose
Alessandra Ferrajoli
Research Funding - Celgene; GlaxoSmithKline